anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a new physiologically active substance consisting of a G protein- conjugated type receptor protein having an amino acid sequence either identical with a specific amino acid sequence or substantially identical with the corresponding amino acid sequence with the N-terminal bearing a glutamine residue or the like, and useful for e.g. developing regulators for central nervous function, circulatory function, cardiac function, etc. SOLUTION: This new physiologically active substance is a new G protein-conjugated type receptor protein consisting of a polypeptide (amide, ester, salt) containing an amino acid sequence either identical with an amino acid sequence of the formula or substantially identical with the corresponding amino acid sequence with the N- terminal bearing a glutamine residue or pyroglutamic acid residue. This new substance is useful for e.g. developing medicaments including regulators for central nervous function, circulatory function, cardiac function, renal function, urologic function and sensory function.  The above polypeptide is obtained by the following procedure: using human brain-derived poly(A)+RNA as template, a cDNA is synthesized, and then cloned by PCR technique using a primer for synthesizing a partial sequence, the resultant gene is integrated into a vector and then expressed in host cells.
Naloxone hydrochloride injection may be administered intravenously, intramuscularly, or subcutaneously. The most rapid onset of action is achieved by intravenous administration and it is recommended in emergency situations.

Since the duration of action of some opioids may exceed that of naloxone the patient should be kept under continued surveillance. Repeated doses of naloxone should be administered, as necessary.

Intravenous Infusion

Naloxone hydrochloride injection may be diluted for intravenous infusion in 0.9% sodium chloride or 5% dextrose injection. The addition of 2 mg of naloxone hydrochloride in 500 mL of either solution provides a concentration of 0.004 mg/mL. Mixtures should be used within 24 hours. After 24 hours, the remaining unused solution must be discarded. The rate of administration should be titrated in accordance with the patient’s response.

Naloxone hydrochloride injection should not be mixed with preparations containing bisulfite, metabisulfite, long-chain or high molecular weight anions, or any solution having an alkaline pH. No drug or chemical agent should be added to naloxone hydrochloride injection unless its effect on the chemical and physical stability of the solution has first been established.

General

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
the aim of this paper, is to propose a new reference line: the Frontozygomatic-Infraorbital Line (FZ-IOL). This reference line can guide the surgical team planning mandibular angle harmonization, based on the patient's skeletal proportion. The Frontozygomatic-Infraorbital Line has been adopted for symmetrization surgery, masculinization surgery, and in unsatisfactory results of previous orthognathic surgery. From March 2021 to December 2022, 3 patients were treated for severe facial asymmetry affecting mainly the lower third of the face. All cases were planned with the reference FZ-IOL. Patients were treated in the same center, at the Orthognathic Surgery Department of the Instituto Portugues da Face, Lisbon, Portugal. The Frontozygomatic-Infraorbital Line is designed virtually using software to reconstruct a 3D image from a digital imaging and communications in medicine (DICOM) file obtained from a cone beam computer tomography (CBCT). , connecting the two orbital rims. Then, a vertical line, the frontozygomatic line perpendicular to the IOL and passing through the outmost lateral portion of the frontozygomatic suture is drawn. The proposed line demonstrated how establishing appropriate reference lines is crucial for the success of the surgery. The selection of reference lines should be based on the patient's anatomy, the symmetrization process's complexity, and the surgery's desired outcome. The Frontozygomatic-Infraorbital Line represents an adequate reference line for managing mandibular angle lateral projection, improving lower third of the face symmetrization.
Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
The invention relates to the fields of molecular virology and immunology, in particular to application of a non-toxic mutant CRM197 (Cross-Reacting Materials 197) of DT (Diphtheria Toxin) or fragments of the CRM197 used as an intra-molecular adjuvant in fusion protein for enhancing the immunogenicity of interest protein (such as HEV (Hepatitis E Virus) capsid protein, influenza virus M2 protein or immunogenic fragments of the HEV capsid protein and the influenza virus M2 protein) fused with the fusion protein. The invention also relates to a method for enhancing the immunogenicity of the interest protein (such as the HEV capsid protein, the influenza virus M2 protein or the immunogenic fragments of the HEV capsid protein and the influenza virus M2 protein). The method comprises the following steps of carrying out fusion expression on the CRM197 or the fragments of the CRM197 and the interest protein, and forming the fusion protein. The invention also relates to the fusion protein containing the CRM197 or the fragments of the CRM197 and the interest protein (such as the HEV capsid protein, the influenza virus M2 protein or the immunogenic fragments of the HEV capsid protein and the influenza virus M2 protein), wherein the immunogenicity of the interest protein is enhanced by the CRM197 or the fragments of the CRM197. The invention also relates to isolated nucleic acid for coding the fusion protein. The isolated nucleic acid comprises a construction body and a carrier of the nucleic acid and host cells containing the nucleic acid. The invention also relates to application of the fusion protein. The fusion protein is used for preparing medicine compositions or vaccines.
Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
Between-group comparisons for pooled placebo-controlled trials in adults revealed no statistically significant differences between risperidone and placebo in mean changes from baseline in ECG parameters, including QT, QTc, and PR intervals, and heart rate. When all risperidone doses were pooled from randomized controlled trials in several indications, there was a mean increase in heart rate of 1 beat per minute compared to no change for placebo patients. In short-term schizophrenia trials, higher doses of risperidone (8-16 mg/day) were associated with a higher mean increase in heart rate compared to placebo (4-6 beats per minute). In pooled placebo-controlled acute mania trials in adults, there were small decreases in mean heart rate, similar among all treatment groups. 

In the two placebo-controlled trials in children and adolescents with autistic disorder (aged 5 to 16 years) mean changes in heart rate were an increase of 8.4 beats per minute in the risperidone  groups and 6.5 beats per minute in the placebo group. There were no other notable ECG changes. 

In a placebo-controlled acute mania trial in children and adolescents (aged 10 to 17 years), there were no significant changes in ECG parameters, other than the effect of risperidone  to transiently increase pulse rate (< 6 beats per minute). In two controlled schizophrenia trials in adolescents (aged 13 to 17 years), there were no clinically meaningful changes in ECG parameters including corrected QT intervals between treatment groups or within treatment groups over time.
ABSTRACT OF THE DISCLOSURE       The invention relates to novel phenylalkylamines of formula   I wherein R1 represents a hydrogen atom, the group -(CH)n-R4 (wherein n is 1 or 2 and R4 represents a hydrogen atom, or a cyano or benzoyl group) or the group-CO-R5 (wherein R5 represents a hydrogen atom, a lower alkoxy group, a benzoyl or benzyloxy group, or a group of the formula -CH2-NH2, -CH(CH3)-NH2, -CH2-NH-CH2-C6H5 or -CH(CH3)-NH-CH2-C6H5); and R3 represents an amino group or a group -NH-CO-R6 (wherein R6 represents a hydrogen atom, a methyl, methoxy, ethoxy, methylthio or ethylthio group) or a group -NH-W-R7 (wherein R7 repre-sents an amino, methylamino or dimethylamino group and W represents the group -CO- or SO2). The invention also relates to the acid addition salts thereof as well as to processes for their preparation. The novel compounds possess interesting physiological activity and in particular are sympa?homimetically active and exhibit an activity on the central nervous system. The novel com-pounds are thus potentially useful as stabilizers of the circulation and have been found to cause a long-lasting increase in blood pressure. Processes for the production of the novel compounds are described and examples of certain of the novel compounds are given. Pharmaceutical compositions containing the novel compounds are described and exemplified. ]
After oral administration, cycloserine is readily absorbed from the gastrointestinal tract, with peak blood levels occurring in 4 to 8 hours.   
Blood levels of 25 to 30 μg/mL can generally be maintained with the usual dosage of 250 mg twice a day, although the relationship of plasma levels to dosage is not always consistent. Concentrations in the cerebrospinal fluid, pleural fluid, fetal blood, and mother’s milk approach those found in the serum. Detectable amounts are found in ascitic fluid, bile, sputum, amniotic fluid, and lung and lymph tissues. Approximately 65 percent of a single dose of cycloserine can be recovered in the urine within 72 hours after oral administration. The remaining 35 percent is apparently metabolized to unknown substances. The maximum excretion rate occurs 2 to 6 hours after administration, with 50 percent of the drug eliminated in 12 hours.
Standardized hemodialysis treatments 3x4hours/week. Intervention: "EvoCit procedure" using a heparin-grafted AN69ST dialyzer in combination with a citric acid enriched dialysate without any systemic anticoagulation.
The optimal analgesia regimen after open cardiac surgery is unclear. The aim of this study was to investigate the beneficial effects of continuous transversus thoracis muscle plane (TTMP) blocks initiated before surgery on open cardiac surgery outcomes. A group of 110 patients were randomly allocated to either receive bilateral continuous TTMP blocks (TTP group) or no nerve block (SAL group). The primary endpoint was post-operative pain at 4, 8, 16, 24, 48 and 72 h after extubation at rest and exercise. The secondary outcome measures included analgesia requirements (sufentanil and flurbiprofen axetil administration), time to extubation, incidence of reintubation, length of stay in the ICU, incidence of post-operative nausea and vomiting (PONV), time until return of bowel function, time to mobilization, urinary catheter removal and length of hospital stay. The length of stay in the ICU and length of hospital stay were significantly longer in the SAL group than in the TTP group. NRS scores at rest and exercise were significantly lower in the TTP group than in the SAL group at all time points. The TTP group required significantly less intraoperative and post-operative sufentanil and post-operative dynastat consumption than the SAL group. Time to extubation, time to first flatus, time until mobilization and time until urinary catheter removal were significantly earlier in the TTP group than in the SAL group. The incidence of PONV was significantly lower in the TTP group. Bilateral continuous TTMP blocks provide effective analgesia and accelerate recovery in patients undergoing open heart valve replacement surgery.
FXS is the most common inherited form of intellectual disability (ID). The typical male has an IQ (intelligence quotient) of 50 to 55, but involvement ranges from mild to severe. Females are generally less affected and have a broader range in function. Some have severe ID and adaptive impairments, but most have a normal or borderline intellectual ability. This wide range in cognitive skills leads to variable ability to make choices and live independently. Most research on individuals with FXS has been noninvasive, limited to parent surveys and psychological assessments. Studies such as these evoke few if any major ethical concerns, so the consent process typically involves a straightforward parental consent. Some studies have drawn blood, collected saliva, measured heart rate, or used neuroimaging, but until recently there has been a paucity of treatment research. This scenario has changed dramatically in the past several years. Advances in understanding the molecular basis of FXS have led to a new generation of treatments, and clinical trials are under way using a variety of compounds. The possibility of side effects and the potential for significant changes in behavior and ability elevate to a new level the importance of obtaining meaningful consent, not only from parents, but also from individuals with FXS. Researchers and Institutional Review Board (IRB) members need data to guide decisions about involving individuals with FXS in the consent process. Unfortunately, little is known about the extent to which individuals with FXS can be or are involved in decisions about research participation. This project will assess the range of decisional capacity in FXS, identify factors associated with individual differences in decisional capacity, validate a rating scale for categorizing decisional capacity, and develop a novel tablet-based decision aid technology to assist researchers and clinicians in maximizing decisional capacity and consent. This study will work toward achieving two overarching aims: 1) Characterize and explain individual differences in decisional capacity in FXS, 2) Design and evaluate the effect of a tablet-based decision aid on participation in the consent process for a hypothetical clinical trial. Ultimately, this study will provide important information about the nature of decisional capacity in FXS and validate a novel intervention to maximize successful participation in the consent process.
INTRODUCTION: The aim of this work was to explore the use of an original once-weekly radiotherapy fractionation in elderly or frail patients with recurrence or metastasis from different solid malignancies.
MATERIAL AND METHODS: A retrospective analysis was conducted on 29 patients treated from 2011 to 2019 with a once-weekly radiotherapy schedule. Patients received a median dose of 27.5 Gy, with weekly fractions of 4-5 Gy over 7-10 weeks. The treatment aimed at both palliative and cytoreductive objectives. Primary endpoints were feasibility and compliance, secondary outcome was acute toxicity.
RESULTS: All patients completed the planned radiotherapy without interruptions. Acute toxicity was mild, with only one patient developing grade 3 toxicity (bowel perforation). Three months post-treatment, 74% of patients experienced symptom relief and tumor response. One-year local control rates were 26.7%, and treatment was generally well-tolerated.
CONCLUSION: This once-weekly hypofractionated radiotherapy regimen demonstrated feasibility, good tolerance, and promising tumor response in frail and elderly patients. Although limited by a small sample size, the approach offers a practical alternative for patients unable to undergo conventional daily radiotherapy. Further studies on larger cohorts are required to validate these findings.
Abrupt discontinuation or dosage reduction of PARNATE has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy.

There have been spontaneous reports of adverse reactions occurring upon discontinuation of MAOIs, particularly when abrupt, including dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g. paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these reactions are generally self-limiting, there have been reports of prolonged discontinuation symptoms.

Patients should be monitored for these symptoms when discontinuing treatment with PARNATE. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible [see Dosage and Administration (2.3) and Adverse Reactions (6)].
General practitioners (GPs) examine patients who attend a primary health care center. In the intervention group the computer-based clinical decision support tool "Nevus doctor" in a first step assists doctors in the process of selecting skin lesions that are suggestive of cancer. In the next step a given skin lesion is photographed using a dermatoscope attached to the lens of the camera. The dermatoscopic image is then processed by the computer program "Nevus doctor" and a preliminary result is presented. Finally the GP reviews the result and assesses the clinical significance of the output by using guidelines presented by "Nevus doctor". The patient is subsequently referred to a dermatologist and a complete skin examination is performed. The assessment of the dermatologist serves as the gold standard.
All patients will be administered PD1-Vaxx intramuscularly into the deltoid region of the upper arm on days 1,15 and 29. Patients will undergo resection surgery within 21 days, but up to 42 days of completing trial treatment.
The invention provides a preparation method for preparing a gelata containing shikone extract. According to the method, firstly, the shikonin is ground and added into a sulfuric acid solution with the mass concentration thereof to be 1%. The obtained product is stirred, heated, extracted and cooled to obtain an extract liquid. The pH value of the extract liquid is adjusted to be 8.0 to 10.0. After the standing process of the extract liquid, an obtained precipitate is removed, and the pH value of an obtained supernatant is adjusted to be 1.0 to 3.0. After that, the sodium chloride is added, and the obtained product is fed into the macroporous resin for being absorbed. An obtained permeate liquid is filtered by an ultrafiltration membrane and an obtained ultrafiltration permeate liquid is subjected to concentration under vacuum, cooling and crystallization. An obtained crystal substance is filtered out and dried and then an extract is obtained. Finally, the extract is added into glycerol, and the obtained product is stirred uniformly. After that, Carbomer, triethanolamine, polyoxyethylene hydrogenated castor oil, potassium sorbate, chloretone, water, menthol, succinic acid and guar gum are added and stirred to obtain the gelata. According to the technical scheme of the invention, the gelata containing the shikone extract eliminates the redness caused by mosquito bites, and relieves the mild skin trauma and the buttocks eczema. Meanwhile, the gelata has no stimulation to the skin.
A preparation method of a traditional Chinese medicinal lotion for treating unfailing bedsore belongs to the technical field of traditional Chinese medicine preparation methods. At present, sulfanilamide and antibiotic are generally adopted to treat unfailing bedsore, but have big toxic and side effect. The invention has the following technical scheme: taking Asarum Herb, pepper, Fructus Piperis Longi, cubeb, fennel, leek, galagal rhizome, common cnidium fruit, capsicum, caraway seed, resurrection lily rhizome, monkshood, Tianxiong (Aconitum carmichaeli Debx), shinyleaf pricklyash root, Sarcandra glabra, Radix Tyolphroae, cudweed herb, Toddalia asiatica, pawpaw, roughhair fig root, cortex acanthopanacis, achyranthes root, gartersnake, Blumea balsamifera, Chinese photinia leaf, serissa serissoides, dry ginger and licorice, immersing the above traditional Chinese medicines into water, decocting by slow fire, and filtering to remove slag. The decocted medical solution is the traditional Chinese medicine lotion for treating unfailing bedsore. The preparation method provided by the invention has advantages of less toxic and side effect of the prepared traditional Chinese medical solution, short treatment course, high cure rate and appropriate combination of main and auxiliary medicines. In addition, the application of the traditional Chinese medicine provided by the invention avoids adverse reaction, anaphylactic reaction and toxic response caused by western medicines.
Dose escalation phase: Eligible patients will enter the screening period up to 14 days before the start of treatment. Patients will receive mitoxantrone liposomes combined with cytarabine, with a fixed dose of cytarabine and mitoxantrone liposomes in 3 dose groups: 24 mg/m\^2, 30 mg/m\^2 and 36 mg/m\^2. The starting dose will be 24 mg/m\^2, and the "3+3" principle is adopted for the escalation. If the maximum tolerated dose is not explored at the preset maximum dose (36 mg/m\^2), the investigator and the sponsor will determine whether to continue the dose escalation, and it is necessary to ensure that 6 patients complete the dose-limiting toxicity (DLT) observation under this dose group. The treatment period includes 2 cycles with each cycle lasting 28 days. Cycle 1 is the DLT observation period and Cycle 2 is the extended dosing period. Mitoxantrone hydrochloride liposome injection will be given on the first day of each cycle, and cytarabine will be given every 12 hours on Day 1, 3, and 5 of each cycle. Patients who do not experience a DLT in the first cycle and achieve is at least PR, may enter the extended dosing period and be treated with the original regimen in Cycle 2. Patients who have completed 2 cycles and have a DLT in the first cycle or have not achieved PR will be withdrawn from treatment.

Dose expansion phase: Newly treated AML or R/R AML patients will be included and divided into two cohorts. Eligible patients will enter the screening period up to 14 days before receiving treatments. The treatment period is 2 cycles, and each cycle is 28 days. Mitoxantrone hydrochloride liposome injection will be given on the first day of each cycle, whose dose size will be determined by the investigator and the sponsor based on the results of the previous study. Cytarabine will be given on Day 1-7 of each cycle for the treatment-naïve group, and on Day 1, 3 and 5 of each cycle for the R/R group. Patients will take 1 cycle of therapy and will be assessed for response at the end of the 1st cycle. After the efficacy evaluation, the patient may receive a second cycle of chemotherapy at the investigator's discretion. And patients whose curative effect do not reach PR will be withdrawn from treatment.